Luye Life Sciences Group Sharpens its Focus on Japan with 10 New Drugs Planned For The Coming Decade
Luye Pharma to Conduct Clinical Trials for Its New IDO Anti-Tumor Drug An Important Initiative for Expanding Its Global Footprint in Immune-Oncology Therapeutic Area
U.S. FDA Exempts Risperidone from Pediatric Clinical Trials, Good News Keeps Coming for Luye Pharma’s CNS Products
Luye Pharma Obtained FDA’s Green Light to Exempt Its Investigational CNS Drug from Phase II Clinical Trial, Market Launch is Expected to be Accelerated
Good News！Luye Pharma Nanjing Receives China HR Practice & Innovation Gold Award
Luye Pharma New Drug Phase II Clinical Trial Shows Positive Results, CNS Product Pipelines Release Potential as a Global Hit
Luye Pharma Group Invests in Exicure for the Development of Novel Nucleic Acid Therapeutics
Luye Pharma Boosts Its Product Portfolio in Biomedicine by Acquiring 2 Biological Antibodies
Luye Life Sciences Expands Global Reach as New Boston R&D Center Opens
Luye Pharma Has Obtained Approval to Develop Buprenorphine Transdermal Patches in China
